Literature DB >> 1689170

Medical management of benign prostatic hyperplasia with androgen suppression.

J D McConnell1.   

Abstract

Many types of nonsurgical therapy, including balloon dilation, hyperthermia, adrenergic blockade, and hormonal therapy, have been used for the treatment of benign prostatic hyperplasia (BPH). Antiandrogen therapy has been the most extensively studied form of hormonal treatment for BPH, although estrogens, antiestrogens, and antiprolactin agents have also been used (Scott and Coffey: Vitam Horm 33:439-465, 1975). The theoretical basis of antiandrogen therapy will be reviewed along with a summary of relevant clinical trials. Recent advances in the development of agents that more selectively inhibit the androgen-dependent growth of the prostate will be presented.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689170     DOI: 10.1002/pros.2990170506

Source DB:  PubMed          Journal:  Prostate Suppl        ISSN: 1050-5881


  14 in total

1.  Medical treatment of benign prostatic hyperplasia.

Authors:  J D Schmidt
Journal:  West J Med       Date:  1991-12

Review 2.  Comparison of the cost-effectiveness of various therapies for common prostatic disorders.

Authors:  E A Amin; M Amin
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

3.  Benign prostatic hyperplasia: an overview.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2005

Review 4.  Medical treatment of benign prostatic hyperplasia.

Authors:  Stephen S Connolly; John M Fitzpatrick
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

5.  Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling.

Authors:  Xinhua Zhang; Ning Zang; Yu Wei; Jin Yin; Ruobing Teng; Allen Seftel; Michael E Disanto
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-25       Impact factor: 4.310

Review 6.  The Role of Heat Shock Protein 70 Subfamily in the Hyperplastic Prostate: From Molecular Mechanisms to Therapeutic Opportunities.

Authors:  Xun Fu; Huan Liu; Jiang Liu; Michael E DiSanto; Xinhua Zhang
Journal:  Cells       Date:  2022-06-28       Impact factor: 7.666

Review 7.  Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia.

Authors:  D H Peters; E M Sorkin
Journal:  Drugs       Date:  1993-07       Impact factor: 9.546

Review 8.  Benign prostatic hyperplasia. Current pharmacological treatment.

Authors:  M Jønler; M Riehmann; R C Bruskewitz
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 9.  The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Chris M Gonzalez; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

10.  Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH).

Authors:  Angelo J Cambio; Christopher P Evans
Journal:  Ther Clin Risk Manag       Date:  2007-03       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.